323 related articles for article (PubMed ID: 38361928)
1. Translational and oncologic significance of tertiary lymphoid structures in pancreatic adenocarcinoma.
Gao Z; Azar J; Zhu H; Williams-Perez S; Kang SW; Marginean C; Rubinstein MP; Makawita S; Lee HS; Camp ER
Front Immunol; 2024; 15():1324093. PubMed ID: 38361928
[TBL] [Abstract][Full Text] [Related]
2. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer.
J Gunderson A; Rajamanickam V; Bui C; Bernard B; Pucilowska J; Ballesteros-Merino C; Schmidt M; McCarty K; Philips M; Piening B; Dubay C; Medler T; Newell P; Hansen P; Tran E; Tang E; Bifulco C; Crittenden M; Gough M; Young KH
Oncoimmunology; 2021 Mar; 10(1):1900635. PubMed ID: 33796412
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
[TBL] [Abstract][Full Text] [Related]
4. Integrated analysis of tertiary lymphoid structures in relation to tumor-infiltrating lymphocytes and patient survival in pancreatic ductal adenocarcinoma.
Tanaka T; Masuda A; Inoue J; Hamada T; Ikegawa T; Toyama H; Sofue K; Shiomi H; Sakai A; Kobayashi T; Tanaka S; Nakano R; Yamada Y; Ashina S; Tsujimae M; Yamakawa K; Abe S; Gonda M; Masuda S; Inomata N; Uemura H; Kohashi S; Nagao K; Kanzawa M; Itoh T; Ueda Y; Fukumoto T; Kodama Y
J Gastroenterol; 2023 Mar; 58(3):277-291. PubMed ID: 36705749
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy is associated with suppression of the B cell-centered immune landscape in pancreatic ductal adenocarcinoma.
Rupp L; Dietsche I; Kießler M; Sommer U; Muckenhuber A; Steiger K; van Eijck CWF; Richter L; Istvanffy R; Jäger C; Friess H; van Eijck CHJ; Demir IE; Reyes CM; Schmitz M
Front Immunol; 2024; 15():1378190. PubMed ID: 38629072
[TBL] [Abstract][Full Text] [Related]
6. Tertiary lymphoid structures and their association to immune phenotypes and circulatory IL2 levels in pancreatic ductal adenocarcinoma.
Ahmed A; Köhler S; Klotz R; Giese N; Hackert T; Springfeld C; Zörnig I; Jäger D; Halama N
Oncoimmunology; 2022; 11(1):2027148. PubMed ID: 35127251
[TBL] [Abstract][Full Text] [Related]
7. Distinct Tertiary Lymphoid Structure Associations and Their Prognostic Relevance in HER2 Positive and Negative Breast Cancers.
Liu X; Tsang JYS; Hlaing T; Hu J; Ni YB; Chan SK; Cheung SY; Tse GM
Oncologist; 2017 Nov; 22(11):1316-1324. PubMed ID: 28701569
[TBL] [Abstract][Full Text] [Related]
8. Characterization of intratumoral tertiary lymphoid structures in pancreatic ductal adenocarcinoma: cellular properties and prognostic significance.
Zou X; Lin X; Cheng H; Chen Y; Wang R; Ma M; Liu Y; Dai Z; Tasiheng Y; Yan Y; Hou Q; Ding F; Chen H; Yu X; Wang X; Liu C
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37364934
[TBL] [Abstract][Full Text] [Related]
9. Investigating Tumor-Associated Tertiary Lymphoid Structures in Murine Lung Adenocarcinoma.
Connolly KA; Nader M; Joshi N
Methods Mol Biol; 2018; 1845():259-273. PubMed ID: 30141018
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment
Xu W; Lu J; Liu WR; Anwaier A; Wu Y; Tian X; Su JQ; Qu YY; Yang J; Zhang H; Ye D
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38040418
[TBL] [Abstract][Full Text] [Related]
11. Impact of tertiary lymphoid structures on prognosis and therapeutic response in pancreatic ductal adenocarcinoma.
Merali N; Jessel MD; Arbe-Barnes EH; Ruby Lee WY; Gismondi M; Chouari T; O'Brien JW; Patel B; Osei-Bordom D; Rockall TA; Sivakumar S; Annels N; Frampton AE
HPB (Oxford); 2024 Apr; ():. PubMed ID: 38729813
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer: Emerging field of regulatory B-cell-targeted immunotherapies.
Senturk ZN; Akdag I; Deniz B; Sayi-Yazgan A
Front Immunol; 2023; 14():1152551. PubMed ID: 37033931
[TBL] [Abstract][Full Text] [Related]
13. Tertiary lymphoid structures in cancer: maturation and induction.
Chen Y; Wu Y; Yan G; Zhang G
Front Immunol; 2024; 15():1369626. PubMed ID: 38690273
[TBL] [Abstract][Full Text] [Related]
14. Tertiary lymphoid structural heterogeneity determines tumour immunity and prospects for clinical application.
Zhang Y; Xu M; Ren Y; Ba Y; Liu S; Zuo A; Xu H; Weng S; Han X; Liu Z
Mol Cancer; 2024 Apr; 23(1):75. PubMed ID: 38582847
[TBL] [Abstract][Full Text] [Related]
15. Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer.
Wang Q; Shen X; An R; Bai J; Dong J; Cai H; Zhu H; Zhong W; Chen W; Liu A; Du J
Front Immunol; 2022; 13():962056. PubMed ID: 36189233
[TBL] [Abstract][Full Text] [Related]
16. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas.
Kinker GS; Vitiello GAF; Diniz AB; Cabral-Piccin MP; Pereira PHB; Carvalho MLR; Ferreira WAS; Chaves AS; Rondinelli A; Gusmão AF; Defelicibus A; Dos Santos GO; Nunes WA; Claro LCL; Bernardo TM; Nishio RT; Pacheco AM; Laus AC; Arantes LMRB; Fleck JL; de Jesus VHF; de Moricz A; Weinlich R; Coimbra FJF; de Lima VCC; Medina TDS
Gut; 2023 Oct; 72(10):1927-1941. PubMed ID: 37230755
[TBL] [Abstract][Full Text] [Related]
17. Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.
Zhang WH; Wang WQ; Han X; Gao HL; Xu SS; Li S; Li TJ; Xu HX; Li H; Ye LY; Lin X; Wu CT; Long J; Yu XJ; Liu L
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33055204
[TBL] [Abstract][Full Text] [Related]
18. Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies.
N J; J T; Sl N; Gt B
Oncoimmunology; 2021 Mar; 10(1):1900508. PubMed ID: 33854820
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic targets to enhance antitumor immune response through the induction of tertiary lymphoid structures.
Omotesho QA; Escamilla A; Pérez-Ruiz E; Frecha CA; Rueda-Domínguez A; Barragán I
Front Immunol; 2024; 15():1348156. PubMed ID: 38333212
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity of tertiary lymphoid structures in cancer.
You X; Koop K; Weigert A
Front Immunol; 2023; 14():1286850. PubMed ID: 38111571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
